184
Participants
Start Date
October 31, 2011
Primary Completion Date
February 28, 2013
Study Completion Date
February 28, 2013
Epoetin
Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous \[IV\] or subcutaneous \[SC\]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of \<11 g/dL.
Peginesatide
Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at \<11 g/dL.
Research Facility, San Antonio
Research Facility, San Diego
Research Facility, San Jose
Research Facility, Sacramento
Research Facility, North Brunswick